33.86
price up icon0.27%   0.09
after-market アフターアワーズ: 33.80 -0.06 -0.18%
loading
前日終値:
$33.77
開ける:
$33.5
24時間の取引高:
9.03M
Relative Volume:
0.95
時価総額:
$39.43B
収益:
$17.41B
当期純損益:
$1.43B
株価収益率:
27.80
EPS:
1.2182
ネットキャッシュフロー:
$1.00B
1週間 パフォーマンス:
-1.05%
1か月 パフォーマンス:
+4.09%
6か月 パフォーマンス:
+87.59%
1年 パフォーマンス:
+107.48%
1日の値動き範囲:
Value
$33.04
$33.88
1週間の範囲:
Value
$33.04
$34.92
52週間の値動き範囲:
Value
$12.46
$37.34

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile

Name
名前
Teva Pharmaceutical Industries Ltd Adr
Name
セクター
Healthcare (1111)
Name
電話
972 (3) 914-8213
Name
住所
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Name
職員
32,842
Name
Twitter
@TevaUSA
Name
次回の収益日
2026-01-28
Name
最新のSEC提出書
Name
TEVA's Discussions on Twitter

Compare TEVA vs TAK, ZTS, HLN, UTHR

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
33.86 39.33B 17.41B 1.43B 1.00B 1.2182
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
18.75 58.54B 29.85B 776.90M 4.35B 0.2408
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
131.10 54.78B 9.47B 2.67B 2.28B 6.0218
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
11.07 47.92B 14.26B 1.98B 2.47B 0.4327
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
503.90 21.68B 3.13B 1.27B 1.12B 26.39

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-12-09 開始されました Barclays Overweight
2025-12-05 開始されました Scotiabank Sector Outperform
2025-06-06 開始されました Goldman Buy
2025-05-28 開始されました Truist Buy
2025-05-12 アップグレード JP Morgan Neutral → Overweight
2024-07-10 アップグレード Argus Hold → Buy
2024-03-08 アップグレード JP Morgan Underweight → Neutral
2024-02-12 アップグレード Piper Sandler Neutral → Overweight
2024-01-23 アップグレード Jefferies Hold → Buy
2024-01-03 アップグレード Piper Sandler Underweight → Neutral
2023-12-18 開始されました HSBC Securities Buy
2023-11-27 アップグレード UBS Neutral → Buy
2023-07-06 アップグレード UBS Sell → Neutral
2023-05-25 開始されました Morgan Stanley Equal-Weight
2023-05-18 アップグレード Evercore ISI In-line → Outperform
2023-01-19 ダウングレード Jefferies Buy → Hold
2022-11-14 ダウングレード JP Morgan Neutral → Underweight
2022-11-04 ダウングレード UBS Neutral → Sell
2022-10-21 再開されました Jefferies Buy
2022-08-05 アップグレード BofA Securities Neutral → Buy
2022-06-14 再開されました UBS Neutral
2022-05-17 アップグレード BofA Securities Underperform → Neutral
2022-05-04 ダウングレード Piper Sandler Neutral → Underweight
2022-04-05 アップグレード Barclays Equal Weight → Overweight
2022-03-25 アップグレード Bernstein Mkt Perform → Outperform
2022-01-27 ダウングレード Argus Buy → Hold
2021-10-28 ダウングレード Raymond James Outperform → Mkt Perform
2021-05-04 ダウングレード UBS Buy → Neutral
2021-04-07 再開されました RBC Capital Mkts Sector Perform
2020-11-25 開始されました Oppenheimer Perform
2020-08-06 アップグレード Barclays Underweight → Equal Weight
2020-07-27 再開されました Goldman Neutral
2020-06-01 アップグレード SunTrust Hold → Buy
2020-04-24 再開されました Citigroup Neutral
2020-04-06 アップグレード UBS Neutral → Buy
2020-02-24 ダウングレード Edward Jones Hold → Sell
2019-11-12 アップグレード JP Morgan Underweight → Neutral
2019-10-17 アップグレード Gabelli & Co Hold → Buy
2019-08-07 ダウングレード Evercore ISI Outperform → In-line
2019-07-19 開始されました Wolfe Research Peer Perform
2019-07-15 ダウングレード Morgan Stanley Equal-Weight → Underweight
2019-07-10 再開されました Credit Suisse Neutral
2019-07-05 アップグレード Argus Hold → Buy
2019-06-11 開始されました Barclays Underweight
2019-06-03 アップグレード Oppenheimer Perform → Outperform
2019-05-30 ダウングレード BofA/Merrill Buy → Underperform
2019-05-28 ダウングレード UBS Buy → Neutral
2019-03-20 開始されました SunTrust Hold
2019-03-07 再開されました UBS Buy
すべてを表示

Teva Pharmaceutical Industries Ltd Adr (TEVA) 最新ニュース

pulisher
11:12 AM

J&J Stock Up 38% in 6 Months: Should You Buy, Sell or Hold? - Finviz

11:12 AM
pulisher
Feb 26, 2026

Where is Teva Pharmaceutical Industries Limited (TEVA) Headed? - Finviz

Feb 26, 2026
pulisher
Feb 25, 2026

Corcept's Q4 Earnings and Revenues Fall Short of Estimates - Finviz

Feb 25, 2026
pulisher
Feb 23, 2026

FDA Accepts Teva's New Long-Acting Schizophrenia Treatment Application - Benzinga

Feb 23, 2026
pulisher
Feb 22, 2026

Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Its Strong Recent Share Price Momentum - Sahm

Feb 22, 2026
pulisher
Feb 20, 2026

Truist Boosts Teva (TEVA) Stock Target Amid Pipeline Growth Opportunities - Finviz

Feb 20, 2026
pulisher
Feb 20, 2026

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults - Sahm

Feb 20, 2026
pulisher
Feb 19, 2026

Teva And Sanofi Duvakitug Data Support IBD Pipeline And Growth Story - Sahm

Feb 19, 2026
pulisher
Feb 18, 2026

Goldman Sachs See Teva Pharmaceutical Industries Limited (TEVA) Driving Double-Digit Earnings Growth Through 2026 - Finviz

Feb 18, 2026
pulisher
Feb 18, 2026

Teva Pharmaceutical Industries Ltd (TEVA) Stock Price, Trades & News - GuruFocus

Feb 18, 2026
pulisher
Feb 18, 2026

Teva’s Duvakitug Data Puts Ulcerative Colitis And Crohn’s Bet In Focus - Sahm

Feb 18, 2026
pulisher
Feb 17, 2026

Should You Invest in Teva Pharmaceutical (TEVA), Here's What the Street Has to Say - Finviz

Feb 17, 2026
pulisher
Feb 12, 2026

Teva (TEVA) Is Down 5.2% After Returning To Profitability On Innovation-Led Revenue Shift – What’s Changed - Sahm

Feb 12, 2026
pulisher
Feb 10, 2026

Teva Pharmaceutical Industries (NYSE:TEVA) Valuation In Focus Amid Momentum - Kalkine Media

Feb 10, 2026
pulisher
Feb 10, 2026

Here's What Analysts Are Saying About Teva Pharmaceutical (TEVA) Post Earnings - Finviz

Feb 10, 2026
pulisher
Feb 10, 2026

Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Recent Share Price Momentum And Biosimilar Growth Hopes - Sahm

Feb 10, 2026
pulisher
Feb 09, 2026

A Look Into Teva Pharmaceutical Indus Inc's Price Over Earnings - Sahm

Feb 09, 2026
pulisher
Feb 04, 2026

Barclays Raises Teva Pharmaceutical (TEVA) PT to $38 Following Strong Q4 Earnings Beat - Finviz

Feb 04, 2026
pulisher
Feb 04, 2026

Teva Canada Announces Approval of Expanded Indication of [Pr]AJOVY® (fremanezumab solution for subcutaneous injection), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine - Sahm

Feb 04, 2026
pulisher
Feb 04, 2026

Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory - Finviz

Feb 04, 2026
pulisher
Feb 03, 2026

Teva Canada Mayzent Deal Supports Neuroscience Focus And Valuation Debate - Sahm

Feb 03, 2026
pulisher
Feb 03, 2026

FedEx Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Feb 03, 2026
pulisher
Feb 03, 2026

Earnings call transcript: Teva Q4 2025 earnings beat expectations, stock rises - Investing.com

Feb 03, 2026
pulisher
Feb 02, 2026

Assessing Teva Pharmaceutical Industries’ Valuation After Strong 2025 Earnings And Analyst Upgrades - Sahm

Feb 02, 2026
pulisher
Feb 01, 2026

Teva (TEVA) Is Up 7.1% After 2025 Earnings Highlight Branded-Drugs Momentum And Pipeline Progress - Sahm

Feb 01, 2026
pulisher
Jan 31, 2026

Analysts See Pipeline Catalysts Driving Teva Pharmaceutical Industries Limited (TEVA)'s 2026 Growth Despite Revenue Headwinds - Finviz

Jan 31, 2026
pulisher
Jan 31, 2026

Jim Cramer Highlights Teva Pharmaceutical's Growth Under CEO Richard Francis - Finviz

Jan 31, 2026
pulisher
Jan 30, 2026

Is Teva Pharmaceutical Industries (TEVA) Still Attractive After A 92% One-Year Share Price Surge - Sahm

Jan 30, 2026
pulisher
Jan 30, 2026

Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 12-Month High Following Earnings Beat - Defense World

Jan 30, 2026
pulisher
Jan 29, 2026

Teva Balances Huntington’s Disease Outreach With Branded Drug Transformation - Sahm

Jan 29, 2026
pulisher
Jan 29, 2026

TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth - Finviz

Jan 29, 2026
pulisher
Jan 29, 2026

What Makes Teva Pharmaceuticals (TEVA) a Successful Brand? - Finviz

Jan 29, 2026
pulisher
Jan 29, 2026

Teva Pharma stock hits 52-week high at 33.42 USD By Investing.com - Investing.com Nigeria

Jan 29, 2026
pulisher
Jan 29, 2026

Teva Pharma stock hits 52-week high at 33.42 USD - Investing.com

Jan 29, 2026
pulisher
Jan 28, 2026

Teva Pharmaceutical Industries (NYSE:TEVA) Earnings Margin Recovery Challenges High P/E Valuation Narrative - Sahm

Jan 28, 2026
pulisher
Jan 28, 2026

Teva To See Generics Loss From Revlimid in 2026, but Innovative Portfolio Drives Margin Expansion - morningstar.com

Jan 28, 2026
pulisher
Jan 28, 2026

Teva's Flagship Drugs Hit $1 Billion Milestone, Raises Confidence In 2026 Outlook - Sahm

Jan 28, 2026
pulisher
Jan 28, 2026

Earnings call transcript: Teva beats Q4 2025 EPS forecast, stock dips - Investing.com

Jan 28, 2026
pulisher
Jan 23, 2026

Assessing Teva (TEVA) Valuation As Guidance Driven Momentum Lifts Long Term Profit Expectations - Sahm

Jan 23, 2026
pulisher
Jan 21, 2026

The Truth About Teva Pharmaceutical (ADR): Why Everyone Is Suddenly Watching This Stock - AD HOC NEWS

Jan 21, 2026
pulisher
Jan 19, 2026

Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Results? - Finviz

Jan 19, 2026
pulisher
Jan 19, 2026

Sodium Chloride Injections Market, Global Forecast 2026-2032 - GlobeNewswire Inc.

Jan 19, 2026
pulisher
Jan 18, 2026

This pharma stock “is beating everything”, investor says - Cantech Letter

Jan 18, 2026
pulisher
Jan 16, 2026

How Long-Term Profit Targets and TEV-‘408 Funding At Teva Pharmaceutical (TEVA) Has Changed Its Investment Story - Sahm

Jan 16, 2026
pulisher
Jan 15, 2026

Is Teva (TEVA) Still Reasonably Priced After A 195% Three Year Share Price Gain - Sahm

Jan 15, 2026

Teva Pharmaceutical Industries Ltd Adr (TEVA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
drug_manufacturers_specialty_generic HLN
$11.07
price up icon 2.88%
drug_manufacturers_specialty_generic ZTS
$131.10
price up icon 1.03%
$503.90
price up icon 0.06%
drug_manufacturers_specialty_generic TAK
$18.75
price up icon 1.19%
$14.93
price down icon 2.10%
大文字化:     |  ボリューム (24 時間):